Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Monotherapy in Chinese T2D Patients
NCT01214239Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin with Placebo (2 arms). Primary endpoint: HbA1c Change From Baseline at 24 weeks. Started Oct 2010; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01214239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214239.